First reports of adverse drug reactions
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - December 21, 2020 Category: Drugs & Pharmacology Source Type: research
Manage antipsychotic-induced akathisia by making changes to the antipsychotic drug regimen and/or adding anti-akathisia agents
AbstractAntipsychotic-induced akathisia (AIA) is a common and distressing adverse effect associated with many first- and second-generation antipsychotics. The risk of developing AIA can be minimized by administering the minimal effective dosage of an antipsychotic, avoiding rapid dose escalation and avoiding antipsychotic polypharmacy. Once AIA is diagnosed, patients should first receive an adjustment in their antipsychotic drug regimen (i.e. stop antipsychotic polypharmacy if applicable, lower the dosage of the antipsychotic medication or switch to an antipsychotic with lower AIA potential). If further intervention is nee...
Source: Drugs and Therapy Perspectives - December 18, 2020 Category: Drugs & Pharmacology Source Type: research
Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists
AbstractGiven the key role of pharmacists as a healthcare resource for patients seeking treatment of headache associated with migraine, this review highlights the burden of migraine, recent advances in preventive migraine therapies, and key takeaways from the most recent migraine management consensus statement. For at least two decades, it has been understood that correct diagnosis of migraine is key to its effective management. Migraine attacks should be treated promptly with acute medications, with preventive treatment for patients with regular, frequent, and/or disabling migraine attacks. Nonetheless, most patients with...
Source: Drugs and Therapy Perspectives - December 5, 2020 Category: Drugs & Pharmacology Source Type: research
Community pharmacists ’ knowledge of and attitudes toward antibiotic use, resistance, and self-medication in Jordan
ConclusionAs many CPs in Jordan have poor knowledge of antibiotics and AR, continual educational interventions to improve this situation are necessary. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 23, 2020 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to referees
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 12, 2020 Category: Drugs & Pharmacology Source Type: research
First reports of adverse drug reactions and interactions
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 10, 2020 Category: Drugs & Pharmacology Source Type: research
Levonorgestrel 52 mg intrauterine system (Levosert ®) /Liletta ® ) in contraception: a profile of its use
AbstractLevosert® (EU)/Liletta® (USA) is a levonorgestrel (LNG)-releasing intrauterine system (IUS) containing 52 mg of LNG. It was the first LNG-releasing IUS approved for use for up to 6 years, with daily LNG release rates being sufficient to provide contraception over at least this time period. In the efficacy population (1600 women aged 16 –35 years) of the key ongoing 10-year ACCESS IUS trial, Levosert/Liletta 52 mg was highly effective in preventing pregnancy and improving bleeding patterns. Levosert/Liletta 52 mg also reduces heavy menstrual bleeding (HMB), with no differences in improvements in HMB outcomes bet...
Source: Drugs and Therapy Perspectives - November 5, 2020 Category: Drugs & Pharmacology Source Type: research
Managing PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) in children
AbstractPeriodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) is an uncommon, often misdiagnosed condition usually affecting children and resolving spontaneously before adolescence. While no long-term adverse effects are known, PFAPA is painful and tiring, causing significant school or work absence for the patient and family. Episodic fevers 3 –6 weeks apart that respond within hours to a single corticosteroid dose support the diagnosis. Daily colchicine usually extends the symptom-free interval. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 4, 2020 Category: Drugs & Pharmacology Source Type: research
Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East
We report the case of a patient in the United Arab Emirates (UAE) with advanced HF who was glucose-6-phosphate dehydrogenase deficient and had a history of type 2 diabetes mellitus with diabetic retinopathy and nephropathy, chronic kidney disease stage II, and hyperlipidemia. He was referred for HT abroad and was subsequently caught in the midst of the COVID-19 pandemic in New York, the US state most affected by the crisis at the time. Despite limited experience with favipiravir, we judged it to be the most appropriate agent with this patient ’s complex history given the lower risk for QT prolongation, no need for renal-...
Source: Drugs and Therapy Perspectives - October 31, 2020 Category: Drugs & Pharmacology Source Type: research
Belimumab in systemic lupus erythematosus: a profile of its use
AbstractBelimumab (Benlysta®), a human immunoglobulin (Ig) G1 λ monoclonal antibody targeting B lymphocyte stimulator, is effective as an add-on to standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab was first approved in 2011 as an intravenous (IV) treatment for adults with SLE. Since then, a subcutan eous formulation of belimumab has been approved in adults and, most recently, IV belimumab has been approved in children aged ≥ 5 years. In adults with active, autoantibody-positive SLE, add-on belimumab improves overall disease activity and flare rates. Beli...
Source: Drugs and Therapy Perspectives - October 31, 2020 Category: Drugs & Pharmacology Source Type: research
Rimegepant orally disintegrating tablets in the acute treatment of migraine: a profile of their use
AbstractRimegepant orally disintegrating tablets (ODT) for sublingual or oral use (Nurtec ™ ODT) are a valuable option for the acute treatment of migraine ± aura in adults, especially those with contraindications, treatment failure, or tolerability issues with triptans. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist, and is the first, and currently only , drug in this class available as an ODT formulation in the USA. A single sublingual dose of rimegepant ODT 75 mg provided freedom from pain, freedom from the most bothersome migraine symptoms (e.g., nausea, phonophobia, photophobia), and...
Source: Drugs and Therapy Perspectives - October 30, 2020 Category: Drugs & Pharmacology Source Type: research
Tofacitinib in ulcerative colitis: a profile of its use
AbstractOral tofacitinib (Xeljanz®) is a first-in-class, small molecule janus kinase (JAK) inhibitor that is approved for the treatment of moderate to severe ulcerative colitis in adults who have inadequately responded to, or are intolerant of, conventional therapy or a biological agent in the EU and in adults who have inadequately responded to, or are intolerant of, a tumour necrosis factor antagonist in the USA. In the pivotal phase 3 trials, tofacitinib induction (10 mg twice daily) and maintenance (5 or 10 mg twice daily) treatment significantly improved clinical and endoscopic findings of ulcerative colitis and healt...
Source: Drugs and Therapy Perspectives - October 28, 2020 Category: Drugs & Pharmacology Source Type: research
Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 28, 2020 Category: Drugs & Pharmacology Source Type: research
Upadacitinib in rheumatoid arthritis: a profile of its use
AbstractUpadacitinib (Rinvoq ™), an oral Janus kinase (JAK) 1 inhibitor, is approved as monotherapy or in combination with nonbiological disease-modifying antirheumatic drugs (DMARDs), including methotrexate, in adult patients with moderate to severely active rheumatoid arthritis (RA) who have responded inadequately to, or wh o are intolerant to one or more DMARD. Across phase 3 trials in patients with RA, once-daily upadacitinib treatment was generally well tolerated and associated with rapid and clinically relevant disease remission or low disease activity when administered as monotherapy or in combination conventional...
Source: Drugs and Therapy Perspectives - October 26, 2020 Category: Drugs & Pharmacology Source Type: research
Impact of clinical pharmacists on adherence to stress ulcer prophylaxis protocol in critically ill Egyptian patients: a comparative study
ConclusionClinical pharmacists ’ daily interventions decreased non-adherence to the SUP protocol, and provided a significant decrease in hospital expenditures with no influence on adverse effects. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 19, 2020 Category: Drugs & Pharmacology Source Type: research
